Premium
P1‐150: Mri and ct criteria for Alzheimer's disease stages diagnostics
Author(s) -
Maksimovich Ivan V.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.348
Subject(s) - atrophy , dementia , stage (stratigraphy) , medicine , clinical dementia rating , parkinsonism , vascular dementia , cerebral atrophy , pathology , magnetic resonance imaging , rating scale , disease , radiology , cardiology , psychology , biology , paleontology , developmental psychology
Background: In clinical practice, certain difficulties are caused by preclinical and early clinical AD stages diagnostics and late AD stages differentiation. To solve this problem and to identify dementia stages during AD, we offer «Tomography Dementia Rating scale» (TDR), which allows using MRI and CT to determine temporal lobes atrophic changes severity and thereby determine AD stage. Methods: The research involved 159 patients with neurodegenerative cerebral lesions. The examination included CDR,MMSE,MRI, CT followed by temporal lobes atrophy degree calculation, cerebral scintigraphy (SG), rheoencephalography (REG), and cerebral angiography (MUGA). 81 patients (aged 34-79) with different AD stages– Test Group. The group was divided: Preclinical stage 9; Early stage (CDR-1) 24; Middle stage (CDR-2) 31; Late stage (CDR-3) 17 patients. 78 patients (aged 38-78) had dementia caused by chronic cerebrovascular insufficiency, atherosclerotic Parkinsonism, Binswanger’s disease, Parkinson’s disease, but did not have AD Control Group. Results:During CT and MRI in all patients with AD, the objective characteristic morphological features were the atrophic changes in the temporal lobes, which ranged from 4 to 62% at various stages of the disease. This gave an opportunity to compose the «Tomography Dementia Rating scale» (TDR) allowing the determination of certain atrophic changes at each AD stage. Preclinical AD stage TDR-0 temporal lobes atrophy with 4-8% tissue mass decrease 9 (100%); Early AD stage mild dementia TDR-1 temporal lobes atrophy with 9-18% tissue mass decrease (corresponds to CDR-1) 24 (100%); Middle AD stage moderate dementia – TDR-2 temporal lobes atrophy with 19-32% tissue mass decrease (corresponds to CDR-2) 31 (100%); Late AD stage severe dementia TDR-3 temporal lobes atrophy with 33-62% tissue mass decrease (corresponds to CDR-3) 17 (100%) patients. These changes are not observed in patients with other neurodegenerative diseases. Conclusions:Temporal lobes atrophy is MRI and CT criteria for AD progress. These changes are present both at preclinical and, accordingly, clinical AD stages. «Tomography Dementia Rating scale» (TDR) is an effective method to objectively determine AD stages.